SANUWAVE Health Inc. is an emerging regenerative medical technology company focused on the development and commercialization of noninvasive, biological response activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures.
The company today announced that the American Medical Association (AMA) has released two Current Procedural Terminology Category III codes for Extracorporeal Shock Wave Technology (ESWT) in would healing: 0299T and 0300T. These codes are a set of tracking codes established by the AMA that permit data collection for emerging technology, services and procedures. The approval followed a growing body of peer-reviewed published clinical data.
SANUWAVE Health’s dermaPACE would be the first and only ESWT device in the United States capable of utilizing these codes which will be implemented on January 1, 2012. The company’s dermaPACE device has been submitted to the US Food and Drug Administration (FDA) as a treatment for diabetic foot ulcers and is awaiting approval.
The release of these Category III codes by the AMA is another major milestone in the company’s commercialization strategy for dermaPACE. After FDA approval, SANUWAVE will work with insurance companies to allow for physician payment of dermaPACE procedures.
For additional information on SANUWAVE Health, please visit its website at www.sanuwave.com